# SpringWorks Therapeutics Inc. (SWTX)

Source: https://www.quantisnow.com/company/SWTX
Generated: 2026-11-19T20:40:28.395Z

- Ticker: SWTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2019
- Website: springworkstx.com

## About

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

## Latest SWTX news and filings

- 2025-10-21 06:00 UTC [SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology](https://www.quantisnow.com/insight/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-6239109)
- 2025-08-18 13:10 UTC [European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors](https://www.quantisnow.com/insight/european-commission-grants-approval-of-ogsiveo-nirogacestat-for-the-treatment-6169613)
- 2025-07-18 15:30 UTC [European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN](https://www.quantisnow.com/insight/european-commission-grants-conditional-approval-of-ezmekly-mirdametinib-for-the-6125174)
- 2025-07-11 10:00 UTC [SEC Form 15-12G filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-springworks-therapeutics-inc-6117401)
- 2025-07-07 20:04 UTC [SEC Form SCHEDULE 13G filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-springworks-therapeutics-inc-6112617)
- 2025-07-02 20:26 UTC [SEC Form 4] [Chief Operating Officer Edris Badreddin returned 169,712 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-edris-badreddin-returned-169712-shares-to-the-6108658)
- 2025-07-02 20:25 UTC [SEC Form 4] [Director Lynch Daniel returned 93,004 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lynch-daniel-returned-93004-shares-to-the-company-closing-6108654)
- 2025-07-02 20:25 UTC [SEC Form 4] [Director Lewis-Hall Freda C returned 24,727 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lewis-hall-freda-c-returned-24727-shares-to-the-company-6108649)
- 2025-07-02 20:24 UTC [SEC Form 4] [Director Hambleton Julie returned 14,155 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hambleton-julie-returned-14155-shares-to-the-company-closing-6108639)
- 2025-07-02 20:24 UTC [SEC Form 4] [Director Fuhrman Alan returned 24,727 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-fuhrman-alan-returned-24727-shares-to-the-company-closing-6108632)
- 2025-07-02 20:23 UTC [SEC Form 4] [Chief Scientific Officer Lin Tai-An returned 33,039 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-tai-an-returned-33039-shares-to-the-6108628)
- 2025-07-02 20:22 UTC [SEC Form 4] [Chief Commercial Officer Ashar Bhavesh returned 62,053 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-ashar-bhavesh-returned-62053-shares-to-the-6108612)
- 2025-07-02 20:21 UTC [SEC Form 4] [Chief Medical Officer Cassidy James returned 81,731 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-cassidy-james-returned-81731-shares-to-the-6108594)
- 2025-07-02 20:21 UTC [SEC Form 4] [Director Mackay Martin returned 20,023 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-mackay-martin-returned-20023-shares-to-the-company-closing-6108577)
- 2025-07-02 20:21 UTC [SEC Form 4] [Director Alban Carlos returned 28,861 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-alban-carlos-returned-28861-shares-to-the-company-closing-6108573)
- 2025-07-02 20:20 UTC [SEC Form 4] [Chief Accounting Officer Nofi Michael returned 30,623 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-accounting-officer-nofi-michael-returned-30623-shares-to-the-6108550)
- 2025-07-02 20:19 UTC [SEC Form 4] [Chief People Officer Pichl Daniel returned 50,762 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-people-officer-pichl-daniel-returned-50762-shares-to-the-6108513)
- 2025-07-02 20:18 UTC [SEC Form 4] [Chief Financial Officer Perier Francis I Jr returned 60,889 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-perier-francis-i-jr-returned-60889-shares-6108510)
- 2025-07-02 20:18 UTC [SEC Form 4] [Chief Executive Officer Islam Saqib returned 954,869 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-islam-saqib-returned-954869-shares-to-the-6108498)
- 2025-07-02 20:17 UTC [SEC Form 4] [General Counsel & Secretary Weinstein Herschel S returned 55,239 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-secretary-weinstein-herschel-s-returned-55239-shares-to-6108493)
- 2025-07-01 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105891)
- 2025-07-01 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105886)
- 2025-07-01 20:10 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105875)
- 2025-07-01 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105867)
- 2025-07-01 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105856)
- 2025-07-01 20:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105845)
- 2025-07-01 20:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-springworks-therapeutics-inc-6105829)
- 2025-07-01 20:03 UTC [SEC Form POSASR filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-springworks-therapeutics-inc-6105729)
- 2025-07-01 14:25 UTC [SEC Form 25-NSE filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-springworks-therapeutics-inc-6105314)
- 2025-07-01 12:38 UTC [SEC Form 8-K] [SpringWorks Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/springworks-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-6105053)
- 2025-06-26 20:45 UTC [SEC Form 8-K] [SpringWorks Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/springworks-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6100739)
- 2025-06-20 12:00 UTC [SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors](https://www.quantisnow.com/insight/springworks-therapeutics-receives-positive-chmp-opinion-for-nirogacestat-for-the-6093098)
- 2025-06-16 10:16 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-springworks-therapeutics-inc-6087037)
- 2025-06-16 10:15 UTC [SEC Form 8-K] [SpringWorks Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/springworks-therapeutics-inc-filed-sec-form-8-k-other-events-6087035)
- 2025-05-28 10:02 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by SpringWorks Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-springworks-therapeutics-inc-6060194)
- 2025-05-23 12:00 UTC [SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN](https://www.quantisnow.com/insight/springworks-therapeutics-receives-positive-chmp-opinion-for-mirdametinib-for-the-6055841)
- 2025-05-15 22:46 UTC [SEC Form 4] [Director Lynch Daniel was granted 10,060 shares, increasing direct ownership by 12% to 93,004 units (SEC Form 4)](https://www.quantisnow.com/insight/director-lynch-daniel-was-granted-10060-shares-increasing-direct-ownership-6044003)
- 2025-05-15 22:45 UTC [SEC Form 4] [Director Lewis-Hall Freda C was granted 10,060 shares, increasing direct ownership by 69% to 24,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-lewis-hall-freda-c-was-granted-10060-shares-increasing-direct-6044000)
- 2025-05-15 22:44 UTC [SEC Form 4] [Director Hambleton Julie was granted 10,060 shares, increasing direct ownership by 246% to 14,155 units (SEC Form 4)](https://www.quantisnow.com/insight/director-hambleton-julie-was-granted-10060-shares-increasing-direct-ownership-6043995)
- 2025-05-15 22:43 UTC [SEC Form 4] [Director Fuhrman Alan was granted 10,060 shares, increasing direct ownership by 69% to 24,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fuhrman-alan-was-granted-10060-shares-increasing-direct-ownership-6043992)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SWTX
- Earnings history: https://www.quantisnow.com/earnings/SWTX
- Dividend history: https://www.quantisnow.com/dividends/SWTX
- Insider transactions: https://www.quantisnow.com/insiders/SWTX
- Options chain: https://www.quantisnow.com/options/SWTX
- SEC 8-K filings only: https://www.quantisnow.com/company/SWTX/8-k
- RSS and alerts for SWTX: https://www.quantisnow.com/docs/rss-feeds.md
